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A progressively increasing life expectancy after liver
transplantation (LT) leads to previously underestimated
long-term complications, in particular renal damage as well
as metabolic and cardiovascular disease [1]. Although the
etiology of kidney damage in LT patients may be multi-
factorial, calcineurin-inhibitor (CNI)-induced nephrotoxi-
city signiﬁcantly contributes to the development of renal
dysfunction after LT [2]. CNIs may cause acute and
chronic nephrotoxicity, with the latter usually being asso-
ciated with structural changes in the kidney [3]. Acute
nephrotoxicity comprises vascular effects such as vaso-
constriction of the afferent arterioles, an increased secre-
tion of vasoconstrictor factors including endothelin and
thromboxane, activation of the renin-angiotensin system
(RAS), and reduction of vasodilatation factors such as
nitric oxide, prostacyclin and prostaglandin E2. Acute
CNI-induced nephrotoxicity may further lead to tubular
damage and/or dysfunction and thrombotic microangiopa-
thy. Chronic CNI-related nephrotoxicity including arterio-
lar hyalinosis, tubular atrophy, interstitial ﬁbrosis, and
glomerular sclerosis is observed in most LT recipients with
long-term CNI therapy [2]. Chronic CNI-related renal
damage is thought to be a consequence of both CNI-
induced hemodynamic changes and direct toxic effects on
renal tubular epithelium. Despite the fact that chronic CNI-
related nephrotoxicity is associated with parenchymal
damage, various clinical studies have shown that CNI dose
reduction or discontinuation results in an improvement of
renal function in the majority of LT patients, thus sug-
gesting a partly dose-dependent nephrotoxic effect and
reversible functional kidney impairment [4]. In addition,
CNI reduction or withdrawal is also associated with
decreased cardiovascular risk in LT patients [5].
CNI sparing protocols in LT patients are usually based
on introduction of mycophenolate mofetil (MMF) or
mammalian target of rapamycin (mTOR) inhibitors (e.g.
sirolimus and everolimus) into the immunosuppressive
regimen. While the latter drug group is still awaiting
approval for clinical use in LT patients, MMF has been has
been clinically established since 1995. MMF is a mor-
pholinoethyl ester prodrug of mycophenolic acid (MPA),
an inhibitor of inositol-monophosphate dehydrogenase that
catalyzes the rate limiting step in de novo purine biosyn-
thesis, thereby speciﬁcally suppressing the proliferation of
T and B lymphocytes. MMF virtually lacks drug-related
nephrotoxicity and does not increase cardiovascular risk.
Complete replacement of CNI with MMF though bears an
increased risk of acute rejection; although, combined MMF
and low dose CNI therapy has been shown to be safe within
this regard in several studies [4]. Gastrointestinal (e.g.
diarrhea) and hematological (e.g. anemia and neutropenia)
disorders are the most important and frequent side effects
associated with MMF therapy, but they seldom require
drug discontinuation [6].
Pageaux et al. [7] were the ﬁrst to report results of a
prospective randomized trial in LT patients comparing a
combined low-dose CNI and MMF regimen with CNI
monotherapy. Median time after LT was approximately
60 months in both groups at start of the trial. In the MMF
group, CNI doses were reduced by at least 50% regardless
of the baseline titer, whereas in MMF-free controls CNI
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compared to the control group, in the MMF/CNI group a
signiﬁcant amelioration of renal function became evident.
In a more recent study from our group [8], LT patients with
renal dysfunction were randomized either to receive MMF
followed by stepwise reduction of CNI with deﬁned min-
imal CNI-trough levels (MMF group), or to continue their
maintenance CNI dose (control group). Time between LT
and enrollment of patients into the study ranged from 12 to
199 months with a mean of 60 months. In our study, CNI
dose was progressively tapered to achieve deﬁned target
trough levels as low as 2–4 ng/ml for tacrolimus and
25–50 ng/ml for cyclosporine A. In the MMF group renal
function improved in 62% of patients, remained stable in
36% and deteriorated in only 2% after 12 months com-
pared with baseline values. In the control group renal
function tended to deteriorate during the study period. Of
all tested variables, younger age at study entry was the only
predictive factor for renal improvement in the MMF group.
This, however, might simply reﬂect an increase in athero-
sclerotic vascular disease with older age.
Some studies have demonstrated that MMF directly
exerts protective effects against inﬂammation and ﬁbrosis
progression. Suggested protective mechanisms include the
inhibition of adhesion molecules involved in the migration
of immune cells towards the allograft, reduced nitric oxide
production with subsequent suppressed allograft injury
via interactions with superoxides, elimination of antigen-
speciﬁc T cells and reduced inﬂammatory cytokine syn-
thesis [9]. MMF in combination with CNI taper has been
shown to ameliorate ﬁbrosis progression, graft inﬂamma-
tion and aminotransferase levels in LT patients with
chronic hepatitis C virus (HCV) infection [10]. In a retro-
spective study including 168 LT recipients with chronic
HCV infection, our group showed that long-term MMF is
associated with superior graft and patient survival rates
compared with patients who received no or short-term
(\6 months) MMF immunosuppressive regimens [11].
Several studies comprising immune and nonimmune-
mediated renal disease have provided evidence that MMF
is effective in reversing structural changes in the kidney.
CNI-associated RAS activation promotes renal interstitial
ﬁbrosis due to inhibition of matrix-metalloproteinase
(MMP) activity leading to enhanced extracellular matrix
accumulation [3]. While most of the favorable renal effects
observed in CNI minimization protocols have been attrib-
uted to the lower or absent CNI exposure, there is some
evidence that MMF may be directly nephroprotective. For
instance, MPA has been shown in vitro to transcriptionally
inhibit collagen expression, enhance the expression of
MMP-1 and to modify the migratory and functional prop-
erties of ﬁbroblasts, thus directly exerting antiﬁbrotic
activities [12]. In an animal model MPA has been
demonstrated to signiﬁcantly reduce glomerular and inter-
stitial injury with pronounced decreases in myoﬁbroblast
inﬁltration and collagen accumulation [13]. A potential
anti-atherosclerotic effect due to the immunomodulatory
function of MMF has also been proposed [14]. In a clinical
study with pancreas–kidney recipients, Nankivell et al. [15]
showed that MMF treatment was associated with notable
reduction in tubulo-interstitial, striped and periglomerular
ﬁbrosis, glomerulosclerosis, mesangial matrix deposition
and arteriolar hyalinosis. In a more recent retrospective
study, Karie-Guigues et al. [16] indicated that introduction
of MMF without decreasing the CNI dose was associated
with an improvement of renal function in the long term.
There is thus accumulating evidence that MMF may
directly exert nephroprotective effects. To date, however, it
is not clear in which patients CNI-related renal dysfunction
is reversible and in which morphological changes persist
despite reduction or withdrawal of CNI. In addition, pub-
lished data about the impact of conversion to MMF and
low-dose CNI on long-term renal function and patient
survival are still limited [17, 18]. Recently, Kornberg et al.
[19] addressed this issue in a prospective study with 63 LT
patients with CNI-induced renal dysfunction. The authors
showed that at 60 months post-conversion, mean creatinine
levels had signiﬁcantly declined and mean glomerular ﬁl-
tration rate had signiﬁcantly increased. Nearly half of the
converted patients had CNI-related renal dysfunction for
more than 2 years. Sustained renal response was observed
in 73.1% of patients; full-dose MMF medication and early
conversion were identiﬁed as independent predictors of
persistent renal function improvement. Sustained renal
response after drug conversion was the most relevant
independent promoter of long-term survival in patients
receiving MMF therapy. Although the study is ﬂawed by
the absence of a comparable control group of patients
receiving CNI monotherapy, the reported results intuitively
suggest a favorable long-term outcome for LT patients
receiving MMF-based immunosuppression.
Based on a review of the literature, combined low-dose
CNI and MMF therapy appears to be safe with regard to
incidenceofallograftrejection[4].However,individualrisk
estimation of acute rejection by genetic and/or immunolog-
ical factors is not yet clinically established. There is some
evidence indicating that CNI treatment reduces the per-
centagesofcirculatingregulatoryTcells(Treg)whichplaya
pivotal role in establishment of immunologic allograft tol-
erance [20]. Treg function critically depends on calcineurin-
dependent interleukin-2 production and CNI have been
shown to interfere with Treg induction in a dose-dependent
manner [21]. Two prospective clinical studies so far spe-
ciﬁcally investigated the immunological risk in LT patients
receiving MMF therapy. Our group previously showed that
the circulating cytotoxic T lymphocyte effector pool
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Foxp3 ? Treg signiﬁcantly increased over time in LT
patients receiving combined low-dose CNI and MMF
therapy as compared to CNI monotherapy [8]. More
recently, Demirkiran et al. [22] indicated that conversion
from CNI to MMF therapy increases both percentage and
CD25expressionofCD4 ? CD25 ? Foxp3 ? Treg.These
clinical ﬁndings suggest that introduction of MMF into the
immunosuppressive regimen may promote immunological
tolerance to allogeneic transplants.
In recent years, prospective controlled trials have
established the clinical safety and efﬁcacy of combined
MMF and low-dose CNI therapy in LT patients, as docu-
mented by low incidence of allograft rejection, and pro-
gressive improvement in renal function as well as in
cardiovascular risk factors [7, 8, 23, 24]. Although most
enrolled patients suffered from chronic CNI-related neph-
rotoxicity for several years, renal function improved in a
signiﬁcant number of converted LT patients. Thus,
improvement of CNI-related nephrotoxicity may still occur
after long lasting CNI exposure. Tentative conversion to
MMF-based immunosuppression should therefore be
encouraged whenever CNI-related renal impairment is
suspected in LT patients. In conclusion, there is emerging
evidence that introduction of MMF into the immunosup-
pressive regimen may improve patient and graft survival
after LT. Further prospective controlled studies are nev-
ertheless needed to determine the therapeutic impact of
MMF on outcome of LT patients in the long term.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
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